Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2007

Althea and Blueshift Combine Technologies for Gene Expression Screening

  • Althea Technologies and Blueshift Biotechnologies report that Althea received a SBIR award from the NHGRI to explore the potential for practical high-throughput and low-cost gene expression analysis.

    The grant proposes the development of gene expression profiling methods that make use of Althea's technology in multiplexed PCR (XP™-PCR)* methods and Blueshift's IsoCyte™ platform. This platform is a high-throughput laser scanner adapted from semiconductor inspection technology that provides multicolor fluorescence, anisotropy, and scatter images for high-content and object-based multiplexed array formats.

    The combined technologies may enable implementation of quantitative gene expression profiling in an automated high-throughput platform, providing highly specific and quantitative results for as many as 768 samples per minute.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »